PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, cementing its position as a leading player in the industry. With the support of prominent investors such as Eight Roads, FIL Capital, and F-Prime, PlasmaGen has successfully raised over ₹600 crore to date, underscoring its potential for growth and innovation.
The funding round is a testament to the company’s commitment to advancing the field of plasma fractionation, a process that involves extracting life-saving therapies from human plasma. PlasmaGen operates one of India’s five plasma fractionation facilities near Bengaluru, which enables the production of critical therapies for the treatment of various diseases. The company’s state-of-the-art facility is equipped with cutting-edge technology, ensuring the highest standards of quality and safety in the production of plasma-derived therapies.
The investment by ViNS Bioproducts, a renowned player in the biotechnology sector, is a strategic move that aims to accelerate PlasmaGen’s growth trajectory. With a strong focus on research and development, PlasmaGen is poised to expand its product portfolio, catering to the increasing demand for plasma-derived therapies in India and globally. The company’s vision is to become a leading global player in the plasma fractionation industry, and this funding round is a significant step towards realizing that goal.
PlasmaGen’s success story is a reflection of the growing importance of the biotechnology sector in India. The country has emerged as a hub for biotech innovation, with several start-ups and established companies making significant contributions to the field. The Indian government has also been actively promoting the biotechnology sector, with initiatives such as the Biotechnology Industry Research Assistance Council (BIRAC) and the Department of Biotechnology (DBT) providing support for research and development, funding, and infrastructure development.
The plasma fractionation industry is a critical component of the biotechnology sector, with plasma-derived therapies playing a vital role in the treatment of various diseases, including hemophilia, immunodeficiency disorders, and infectious diseases. The global demand for plasma-derived therapies is on the rise, driven by an increasing awareness of the importance of these therapies in saving lives. India, with its large population and growing healthcare needs, is an important market for plasma-derived therapies, and PlasmaGen is well-positioned to capitalize on this opportunity.
The company’s commitment to quality, safety, and innovation has earned it a reputation as a trusted player in the industry. With a strong team of scientists, researchers, and industry experts, PlasmaGen is dedicated to advancing the field of plasma fractionation and expanding its product portfolio to cater to the evolving needs of the healthcare sector.
The funding raised by PlasmaGen will be utilized to further enhance its manufacturing capabilities, invest in research and development, and expand its market reach. The company plans to increase its production capacity, enabling it to cater to the growing demand for plasma-derived therapies in India and globally. With a strong focus on innovation, PlasmaGen is exploring new technologies and processes to improve the efficiency and effectiveness of plasma fractionation, ensuring that its products meet the highest standards of quality and safety.
In conclusion, PlasmaGen’s successful funding round is a significant milestone in the company’s journey, marking a new chapter in its growth and expansion. With a strong vision, a commitment to innovation, and the support of prominent investors, PlasmaGen is poised to become a leading global player in the plasma fractionation industry. As the company continues to advance the field of plasma fractionation, it is likely to have a profound impact on the healthcare sector, saving lives and improving the quality of life for patients around the world.
Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
